- Home
- VTVT
as 10-17-2024 4:00pm EST
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HIGH POINT |
| Market Cap: | 31.9M | IPO Year: | 2015 |
| Target Price: | N/A | AVG Volume (30 days): | 9.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.38 - $30.99 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,000,000 | Revenue Growth: | 11011.11% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest vTv Therapeutics Inc. News
VTVT Breaking Stock News: Dive into VTVT Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate
Associated Press Finance
2 months ago
VTv Therapeutics: Q2 Earnings Snapshot
GlobeNewswire
2 months ago
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
MT Newswires
3 months ago
Top Midday Decliners
Benzinga
3 months ago
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks
MT Newswires
3 months ago
Top Premarket Decliners
Clinical Trials Arena
3 months ago
FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold
MT Newswires
3 months ago
vTv Therapeutics' Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold; Shares Sink
Compare VTVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTVT vTv Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.